Literature DB >> 14965710

Oncogenes, granules and breast cancer: what has c-myc to do with apocrine changes?

Fernando C Schmitt, Jorge S Reis-Filho.   

Abstract

This issue of The Breast includes an elegant study by Selim et al. on c-myc gene amplification and protein overexpression in apocrine metaplasia (APM) and apocrine adenosis (AA) of the breast using paraffin-embedded tissue. In their report, the authors observe that all cases of APM and AA harbored c-myc protein overexpression, but no definitive gene amplification was found. Most importantly, they observed that the percentage of cells expressing c-myc in APM and AA was significantly correlated with cell proliferation, as assessed by Ki-67 immunolabeling index. On the basis of their findings and of previously reported studies, the authors suggest that c-myc overexpression occurs in early stages of breast carcinogenesis, that c-myc gene amplification may be a late event, and that in APM and AA c-myc overexpression is related to cell proliferation. Selim et al. findings have brought to our attention two thorny but rather important issues regarding current concepts of apocrine changes and their association with breast carcinomas, and also the role of c-myc in breast carcinogenesis.

Entities:  

Year:  2002        PMID: 14965710     DOI: 10.1054/brst.2002.0480

Source DB:  PubMed          Journal:  Breast        ISSN: 0960-9776            Impact factor:   4.380


  3 in total

1.  c-myc, not her-2/neu, can predict the prognosis of breast cancer patients: how novel, how accurate, and how significant?

Authors:  Fernando C Schmitt; Jorge S Reis-Filho
Journal:  Breast Cancer Res       Date:  2003-04-24       Impact factor: 6.466

2.  Squamous cell carcinoma with apocrine features of the breast: A case report.

Authors:  Yoshiki Naito; Rin Yamaguchi; Masaya Tanaka; Akihiro Saruwatari; Yoshikuni Torii; Takahisa Tsukamoto; Naoyo Nishida; Koichi Higaki
Journal:  Oncol Lett       Date:  2014-01-15       Impact factor: 2.967

3.  MYC functions are specific in biological subtypes of breast cancer and confers resistance to endocrine therapy in luminal tumours.

Authors:  Andrew R Green; Mohammed A Aleskandarany; Devika Agarwal; Somaia Elsheikh; Christopher C Nolan; Maria Diez-Rodriguez; R Douglas Macmillan; Graham R Ball; Carlos Caldas; Srinivasan Madhusudan; Ian O Ellis; Emad A Rakha
Journal:  Br J Cancer       Date:  2016-03-08       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.